LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress [Yahoo! Finance]
Graphite Bio, Inc. (GRPH)
NASDAQ:AMEX Investor Relations:
alabamagraphite.com/investors-page
Company Research
Source: Yahoo! Finance
– Topline data from registration-enabling Phase 3 CLARITY trials for lead assets LNZ100 and LNZ101 expected in April 2024 – – Strong balance sheet with approximately $210 million of cash and cash equivalents, including $53.5 million from a concurrent PIPE financing – SAN DIEGO, March 21, 2024 BUSINESS WIRE )--LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced the completion of its previously announced merger with Graphite Bio, Inc. (previously trading on Nasdaq under the ticker symbol "GRPH") ("Graphite Bio"). The new combined company will operate under the name LENZ Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol "LENZ" on March 22, 2024. "Following the close of this transaction, we believe we are well-positioned to bring the opportunity of a once
Show less
Read more
Impact Snapshot
Event Time:
GRPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRPH alerts
High impacting Graphite Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GRPH
News
- Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers [Seeking Alpha]Seeking Alpha
- Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics [Yahoo! Finance]Yahoo! Finance
- Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz TherapeuticsBusiness Wire
- GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPHBusiness Wire
- Kuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law FirmGlobeNewswire
GRPH
Earnings
- 11/13/23 - Miss
GRPH
Sec Filings
- 3/22/24 - Form 8-K
- 3/19/24 - Form 8-K
- 3/15/24 - Form SEC
- GRPH's page on the SEC website